Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.

(RTTNews) - Telomir Pharmaceuticals, Inc. (TELO), announced its participation in the BIO International Convention 2025, taking place June 16-19 in Boston, as the company advances toward submitting an ...

NRx Pharmaceuticals (NRXP) amended its Investigational New Drug filing for NRX-101 to include the use of NRX-101 in association with Transcranial Magnetic Stimulation for the treatment of depression, ...

The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and its current workload as reasons for the delay, according to a legal filing ...

Repair Biotechnologies Inc. has received encouraging feedback from a pre-IND meeting with the FDA as it works toward an IND filing to conduct a phase Ib study of its REP-0003 mRNA therapy in patients ...

BOULDER, Colo., Jan. 12, 2026 /PRNewswire/ -- Mandara Biopharma Inc., a privately held U.S.-based biopharmaceutical company focused on novel therapies for central nervous system (CNS) disorders, today ...